UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · IEX Real-Time Price · USD
15.79
-0.85 (-5.11%)
At close: Jul 19, 2024, 4:00 PM
16.25
+0.46 (2.91%)
Pre-market: Jul 22, 2024, 7:00 AM EDT
UroGen Pharma Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for UroGen Pharma stock have an average target of 42.88, with a low estimate of 18 and a high estimate of 60. The average target predicts an increase of 171.56% from the current stock price of 15.79.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for UroGen Pharma stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 3 | 3 | 3 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $60 | Strong Buy | Reiterates | $60 | +279.99% | Jul 1, 2024 |
| Ladenburg Thalmann | Ladenburg Thalmann | Strong Buy Maintains $48 → $54 | Strong Buy | Maintains | $48 → $54 | +238.82% | Jun 14, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $32 → $40 | Buy | Maintains | $32 → $40 | +153.32% | Jun 14, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $54 → $60 | Strong Buy | Maintains | $54 → $60 | +279.99% | Jun 14, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $54 | Strong Buy | Reiterates | $54 | +241.99% | May 14, 2024 |
Financial Forecast
Revenue This Year
98.17M
from 82.71M
Increased by 18.68%
Revenue Next Year
155.99M
from 98.17M
Increased by 58.90%
EPS This Year
-3.67
from -3.55
EPS Next Year
-2.95
from -3.67
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 102.8M | 170.7M | 293.8M | 500.3M | 661.7M |
| Avg | 98.2M | 156.0M | 263.2M | 370.5M | 538.2M |
| Low | 92.7M | 128.0M | 231.5M | 245.0M | 416.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 24.2% | 73.9% | 88.3% | 90.1% | 78.6% |
| Avg | 18.7% | 58.9% | 68.7% | 40.8% | 45.2% |
| Low | 12.0% | 30.3% | 48.4% | -6.9% | 12.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -3.59 | -1.69 | -0.50 | 3.39 | 5.99 |
| Avg | -3.67 | -2.95 | -1.84 | -0.14 | 2.75 |
| Low | -3.82 | -3.68 | -3.58 | -3.43 | -0.29 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.